Lam Research and KLA-Tencor Business Combination Update

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lam Research and KLA-Tencor Business Combination Update

FREMONT, CA --(Marketwired - August 10, 2016) - Lam Research Corporation ("Lam") and KLA-Tencor Corporation ("KLA-Tencor") today provided an update on their planned business combination. As previously disclosed, the parties continue to discuss their proposed merger, including potential remedies, with the staff of the Department of Justice (the "DOJ"), and with competition authorities in Korea, Japan and China. The companies continue to believe the transaction is pro-competitive and beneficial to their respective customers, employees and suppliers.

Lam and KLA-Tencor are working diligently to receive the necessary regulatory approvals. However, it has become more likely that obtaining regulatory clearances in one or more of the remaining jurisdictions may extend beyond October 20, 2016, the outside date set forth in the merger agreement.

The companies will announce when clearances are obtained, but they do not plan to comment on specific discussions with regulatory agencies, or comment at this time on action Lam or KLA-Tencor will take if the outside date is reached without obtaining all necessary approvals.

About Lam Research:

Lam Research Corp. ( NASDAQ : LRCX ) is a trusted global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's broad portfolio of market-leading deposition, etch, and clean solutions helps customers achieve success on the wafer by enabling device features that are 1,000 times smaller than a grain of sand, resulting in smaller, faster, more powerful, and more power-efficient chips. Through collaboration, continuous innovation, and delivering on commitments, Lam is transforming atomic-scale engineering and enabling its customers to shape the future of technology. Based in Fremont, Calif., Lam Research is a Nasdaq-100 Index® and S&P 500® company whose common stock trades on the Nasdaq Global Select Market(SM) under the symbol LRCX. For more information, please visit http://www.lamresearch.com . (LRCX-F)

About KLA-Tencor:

KLA-Tencor Corporation, a leading provider of process control and yield management solutions, partners with customers around the world to develop state-of-the-art inspection and metrology technologies. These technologies serve the semiconductor, LED, and other related nanoelectronics industries. With a portfolio of industry standard products and a team of world-class engineers and scientists, the company has created superior solutions for its customers for nearly 40 years. Headquartered in Milpitas, Calif., KLA-Tencor has dedicated customer operations and service centers around the world. Additional information may be found at www.kla-tencor.com . (KLAC-F)

Caution Regarding Forward-Looking Statements:

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Lam's and KLA-Tencor's current expectations, estimates and projections, their respective managements' beliefs, and certain assumptions made by Lam and KLA-Tencor, all of which are subject to change. Forward-looking statements can often be identified by words such as "likely," "plan," "believe," "will," "may," "if," similar expressions, and variations or negatives of these words. Examples of such forward-looking statements include, but are not limited to, statements in this document regarding (i) the proposed transaction between Lam and KLA-Tencor, (ii) Lam's and KLA-Tencor's expectations regarding the benefits of the transaction, (iii) Lam's and KLA-Tencor's expectations regarding the receipt of regulatory clearances for the transaction, (iv) Lam's and KLA-Tencor's plans to comment on receipt of regulatory clearances or discussions with regulatory agencies, and (v) Lam's and KLA-Tencor's expected timetable for completing the transaction. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the merger may not close and if it does close we may not receive the expected benefits of the proposed transaction, such as the scale and breadth of critical technologies and better financial performance for our stockholders; the parties' ability to consummate the transaction; the risk that regulatory approvals required for the merger are not obtained, are not obtained prior to the outside date set forth in the merger agreement, or are obtained subject to conditions that are not anticipated; the risk that the other conditions to the closing of the merger are not satisfied; and the other factors described in Lam's Quarterly Report on Form 10-Q for the quarter ended March 27, 2016, KLA-Tencor's Annual Report on Form 10-K for the year ended June 30, 2016, and the joint proxy statement/prospectus filed by Lam on January 13, 2016 with the Securities and Exchange Commission. Lam and KLA disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this document.

Company Contacts: Lam Research Investor Relations Satya Kumar Phone: 510-572-1615 Email: investor.relations@lamresearch.com KLA-Tencor Investor Relations Ed Lockwood Phone: 408-875-9529 Email: ed.lockwood@kla-tencor.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 74

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 186

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 193

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 218

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 255

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 129

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 372

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 115

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSig Technologies Updates on Merger and Share Issuance Plans

Updated Category News Views 173

BioSig Technologies Provides Merger Update LOS ANGELES and VANCOUVER, British Columbia — BioSig Technologies, Inc. (NASDAQ: BSGM), recently provided a significant update regarding its merger with Streamex Exchange Corporation. The recent developments aim to clarify the status of the merger and ensure all shareholders are informed. Details of the Merger Finalization The...

Continue Reading
De La Rue plc: Key Information on Recent Trading Activities

Updated Category News Views 138

Overview of Recent Trading Activities De La Rue plc has recently made headlines through significant trading activities that reflect its status as a leading player in the security printing and cash management industry. As a key participant in financial and currency-related services, the company often finds itself at the crossroads of public interest and regulatory...

Continue Reading
Spar Nord's Strong Financial Performance in Q1 2025

Updated Category News Views 373

Spar Nord Reports Positive Q1 2025 Financial Results Profit after tax of DKK 491 million and return on equity of 14.0% Spar Nord has kicked off 2025 with a robust profit after tax of DKK 491 million, demonstrating a notable return on equity of 14.0%. While this performance marks a promising start for the year, it has been influenced by declining interest rates impacting...

Continue Reading
Latest Trends in CEO Confidence and Economic Outlook

Updated Category News Views 260

CEO Confidence Insights for Q4 2025 The Conference Board, in partnership with The Business Council, reported a slight decrease in the CEO Confidence measure, which now stands at 48 in the fourth quarter of 2025. This reflects a one-point drop from 49 during the third quarter. The readings below 50 indicate a dominantly negative sentiment among executives. In total, 130...

Continue Reading
Shift in Options Trading: Is Tesla Gaining Momentum Over Nvidia?

Updated Category News Views 301

Shift in Options Trading Dynamics The S&P 500 experienced a modest increase, climbing by around 20 basis points, while the NASDAQ 100 saw a more substantial rise, soaring by an impressive 80 basis points. A significant contributor to this market movement was none other than Tesla (NASDAQ: TSLA), which experienced a remarkable surge of about 20% in its stock price....

Continue Reading